Mounjaro Manufacturing, Supply & Shortage History

How Tirzepatide Works: The Dual-Agonist Mechanism

Tirzepatide is the first FDA-approved dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist 1. The molecule activates both incretin pathways simultaneously, producing greater glycemic control and weight reduction than GLP-1-only agents like semaglutide. In SURPASS-2 (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.46% versus 1.86% for semaglutide 1 mg at 40 weeks, with mean body weight reductions of 12.4 kg versus 6.2 kg 2.

The dual-agonist design matters for manufacturing because tirzepatide is a 39-amino-acid synthetic peptide with a C20 fatty diacid moiety attached at lysine-20 3. This acylation enables albumin binding and extends the half-life to approximately 5 days, which supports once-weekly dosing 4. The structural complexity of the molecule requires highly specialized peptide synthesis and purification processes that cannot be rapidly scaled using conventional small-molecule pharmaceutical infrastructure.

GIP receptor co-activation appears to amplify weight loss through complementary mechanisms. Preclinical data suggest GIP signaling in adipose tissue enhances lipid metabolism and energy expenditure beyond what GLP-1 agonism achieves alone 5. This pharmacological profile generated extraordinary clinical demand that outpaced Eli Lilly's initial production forecasts.

FDA Approval Timeline and Demand Surge

The FDA approved Mounjaro for type 2 diabetes on May 13, 2022 6. Within four months, supply constraints appeared. Prescriptions surged in part because of widespread off-label use for weight management, even before Lilly's obesity-indication filing. By Q4 2022, the FDA's Drug Shortage Database listed multiple tirzepatide pen strengths as limited in availability 7.

On November 8, 2023, the FDA approved tirzepatide 2.5 mg through 15 mg under the brand name Zepbound specifically for chronic weight management in adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity 8. The SURMOUNT-1 trial (N=2,539) had demonstrated 22.5% mean weight loss with tirzepatide 15 mg at 72 weeks versus 2.4% for placebo 9. That result, widely covered in mainstream media, pushed demand far beyond existing capacity.

The dual-brand strategy (Mounjaro for diabetes, Zepbound for obesity) effectively doubled the addressable patient population drawing from the same active ingredient. Lilly's Q1 2024 earnings reported combined Mounjaro/Zepbound revenue of $3.2 billion, a figure that reflected both intense demand and persistent inability to fully meet it.

The Peptide Manufacturing Challenge

Producing tirzepatide at commercial scale involves solid-phase peptide synthesis (SPPS), a process where amino acids are added sequentially to a growing chain anchored to a resin bead 10. Each coupling step must exceed 99% efficiency. For a 39-residue peptide, even small per-step yield losses compound rapidly: 99% efficiency per step yields roughly 67% crude product, while 98% efficiency drops that figure to 45%.

After chain assembly, the C20 fatty diacid must be conjugated at the correct lysine residue without modifying other reactive sites 3. Post-synthesis purification relies on reverse-phase high-performance liquid chromatography (RP-HPLC), which is both time-intensive and solvent-intensive. A single manufacturing batch can require weeks from synthesis initiation to final vialed product.

These technical constraints explain why tirzepatide could not be scaled as quickly as a small-molecule drug like metformin or even a monoclonal antibody produced in bioreactors. Peptide manufacturing lines require specialized equipment, cleanroom environments calibrated for peptide handling, and analytical validation suites to confirm identity, purity, and potency at every stage. Building a new peptide facility from ground-breaking to GMP-qualified production typically requires 3 to 4 years.

Shortage Timeline: 2022 Through 2025

Late 2022. The FDA listed tirzepatide injection on its Drug Shortage Database 7. Initial shortages affected the 5 mg, 7.5 mg, 10 mg, and 12.5 mg KwikPen doses. The 2.5 mg starter dose remained intermittently available. Lilly attributed the shortages to "unprecedented demand" and confirmed no manufacturing quality issues had triggered the constraints.

2023. Shortages persisted throughout the year, with periodic worsening. The 15 mg strength, used by patients on maintenance dosing, became particularly difficult to obtain 11. Pharmacies reported wait times of 2 to 6 weeks for certain strengths. The FDA allowed 503B outsourcing facilities to compound tirzepatide during the official shortage period, a decision that would later become controversial.

Q1-Q2 2024. Following the Zepbound launch, combined tirzepatide demand surged again. The 2.5 mg and 5 mg doses (starter and early titration) faced renewed constraints as new Zepbound patients entered titration 12. Eli Lilly announced several manufacturing milestones, including the activation of new production lines at its Lebanon, Indiana facility.

Late 2024. Supply began improving for most Mounjaro KwikPen strengths. In October 2024, the FDA updated its shortage listing to show that several tirzepatide dose strengths were back to "available" status 13. Lilly's quarterly reports indicated production output had more than doubled compared to Q1 2023. The company also moved to restrict compounded tirzepatide, sending cease-and-desist notices to compounding pharmacies once specific strengths exited shortage status.

Early-to-mid 2025. Most branded tirzepatide pen strengths returned to adequate supply. The FDA removed several dose presentations from the shortage database, though select strengths periodically appeared and disappeared from the list. Spot shortages continued to affect some regional markets and independent pharmacies more than large chain pharmacies with direct wholesale agreements 14.

Eli Lilly's $18 Billion Manufacturing Expansion

Lilly committed the largest pharmaceutical manufacturing investment in its 148-year history to address tirzepatide demand. The scale of this buildout reflects both the size of the obesity/diabetes market and the difficulty of scaling peptide production.

Lebanon, Indiana. Lilly broke ground on a $2.1 billion injectable manufacturing facility in 2022, expanded the commitment to $3.7 billion in 2023, and later announced a total investment exceeding $9 billion across multiple Lebanon campus buildings 15. The site focuses on parenteral (injectable) drug product manufacturing, including fill-finish operations for tirzepatide pens and vials.

Concord, North Carolina. In 2024, Lilly announced a $1.8 billion facility for active pharmaceutical ingredient (API) manufacturing, specifically peptide synthesis 16. API production is the bottleneck in peptide drug supply chains, and this facility was designed to increase upstream synthesis capacity ahead of downstream fill-finish capacity.

Research Triangle Park, North Carolina. An additional facility focused on device assembly and packaging for the KwikPen auto-injector platform.

Limerick, Ireland. Lilly invested approximately $1 billion in European manufacturing capacity, diversifying geographic production risk and serving the EU market, where tirzepatide received EMA approval for type 2 diabetes in September 2022 17.

Kenosha County, Wisconsin. Announced in late 2024, this site was earmarked for $3 billion in investment focused on next-generation manufacturing technologies for injectable medicines.

The total committed investment across all sites exceeded $18 billion by early 2025, making Lilly's tirzepatide buildout one of the largest single-product manufacturing expansions in pharmaceutical history.

The Compounding Controversy

During the FDA-listed shortage, 503A and 503B compounding pharmacies began producing tirzepatide 18. This practice is permitted under the Federal Food, Drug, and Cosmetic Act when a drug is on the FDA shortage list, provided compounders meet specific regulatory requirements.

Compounded tirzepatide reached patients at significantly lower cost. Some telehealth platforms offered compounded tirzepatide vials for $200 to $400 per month, compared to list prices exceeding $1,000 for branded Mounjaro or Zepbound. The FDA received reports of adverse events associated with compounded versions, including injection site reactions and dosing inconsistencies, though no confirmed deaths were directly attributed to compounded tirzepatide 19.

As branded supply recovered, Lilly aggressively pursued legal action against compounders. The FDA's position held that once a specific strength exits shortage status, the compounding exemption no longer applies for that strength 20. This created a rolling legal and regulatory field where some strengths could be compounded and others could not, depending on the current shortage database listing.

The American Association of Nurse Practitioners and several patient advocacy groups argued that removing compounded access before branded pricing became affordable would harm patients 21. Lilly responded by launching single-dose Zepbound vials at reduced list prices ($399 for 2.5 mg, $549 for 5 mg) in late 2024, partially addressing cost concerns.

Quality and Safety During Shortages

Drug shortages create measurable clinical risk. A 2023 analysis published in JAMA Internal Medicine found that GLP-1 receptor agonist shortages led to therapy interruptions in 31% of surveyed patients, with 18% reporting glycemic deterioration during the gap 22. For patients on tirzepatide who experienced forced treatment breaks, the metabolic consequences could include HbA1c increases of 0.5% to 1.2% within 8 to 12 weeks of discontinuation.

The FDA issued guidance urging prescribers to avoid starting new patients on strengths with limited availability and to consider therapeutic alternatives during acute shortage periods 23. Alternatives included semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda), though none replicate tirzepatide's dual GIP/GLP-1 mechanism.

For patients already titrated to higher doses (10 mg, 12.5 mg, 15 mg), stepping down to a lower available dose was generally preferred over complete discontinuation. The Endocrine Society noted that abrupt cessation of incretin therapy may cause rebound hyperglycemia and rapid weight regain 24.

"We advise clinicians to maintain patients on the highest available tirzepatide dose rather than interrupting therapy entirely," stated an Endocrine Society clinical practice guidance update. "Partial dose maintenance preserves more glycemic benefit than a drug holiday."

Current Supply Outlook

As of mid-2025, Eli Lilly reports that manufacturing output for tirzepatide has increased more than threefold compared to the initial launch period. Most Mounjaro and Zepbound KwikPen strengths are listed as "available" on the FDA Drug Shortage Database, though the agency continues to monitor supply 25. The Lebanon, Indiana facility is now operational, and the Concord, North Carolina API plant is expected to reach full production capacity by late 2026.

New capacity coming online should support projected demand growth. Analysts estimate the global GLP-1/GIP agonist market will exceed $100 billion annually by 2030, with tirzepatide capturing a significant share based on its superior efficacy profile demonstrated in head-to-head trials 2. Lilly's pipeline also includes oral tirzepatide and next-generation molecules like retatrutide (a GIP/GLP-1/glucagon triple agonist) 26, both of which will require incremental manufacturing capacity.

"The investments we've made represent the most significant manufacturing expansion in our company's history," noted Lilly's 2024 annual report. "Our goal is to ensure no patient prescribed tirzepatide faces a supply barrier."

Patients currently prescribed Mounjaro who experience difficulty locating their specific dose should contact Lilly's Mounjaro support line or check the FDA's drug shortage page for real-time status updates on each strength 25.